Title (en)

QUINOLINE DERIVATIVES AS INHIBITORS OF AXL/MER RTK AND CSF1R

Title (de)

CHINOLINDERIVATE ALS INHIBITOREN VON AXL/MER-RTK UND -CSF1R

Title (fr)

DÉRIVÉS DE QUINOLÉINE UTILISÉS EN TANT QU'INHIBITEURS D'AXL/MER RTK ET CSF1R

Publication

EP 3774776 A1 20210217 (EN)

Application

EP 19728645 A 20190531

Priority

- US 201862677902 P 20180530
- EP 2019064214 W 20190531

Abstract (en)

[origin: WO2019229251A1] The present invention relates to quinoline derivatives which are inhibitors for Axl/Mer RTK (receptor tyrosine kinase) and CSF1R (colony stimulating factor 1 receptor). These compounds are suitable for the treatment of disorders associated with, accompanied by, caused by or induced by Axl/Mer RTK and CSF1R, in particular a hyperfunction thereof. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly immune-suppressive cancer (such as those cancers with an immunosuppression of innate immunity in a tumor microenvironment (TME), refractory cancer and cancer metastases. They are also useful in the treatment of inflammatory diseases and/or neurodegenerative diseases.

IPC 8 full level

C07D 401/14 (2006.01); **A61K 31/4709** (2006.01); **A61P 35/00** (2006.01); **C07D 401/12** (2006.01)

CPC (source: EP IL KR US)

A61K 31/4709 (2013.01 - IL KR); **A61K 31/501** (2013.01 - IL); **A61P 1/04** (2018.01 - IL); **A61P 3/04** (2018.01 - IL); **A61P 3/10** (2018.01 - IL); **A61P 9/10** (2018.01 - IL); **A61P 11/00** (2018.01 - IL); **A61P 19/10** (2018.01 - IL); **A61P 25/00** (2018.01 - IL); **A61P 25/02** (2018.01 - IL); **A61P 25/04** (2018.01 - IL); **A61P 25/14** (2018.01 - IL); **A61P 25/16** (2018.01 - IL); **A61P 25/28** (2018.01 - IL KR); **A61P 27/06** (2018.01 - IL); **A61P 29/00** (2018.01 - IL KR); **A61P 35/00** (2018.01 - EP IL KR); **A61P 37/02** (2018.01 - IL); **A61P 37/06** (2018.01 - IL); **C07D 401/12** (2013.01 - EP KR US); **C07D 401/14** (2013.01 - EP IL KR US); **C07D 405/14** (2013.01 - IL KR US); **C07D 409/14** (2013.01 - IL KR US); **C07D 413/14** (2013.01 - IL)

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2019229251 A1 20191205; AU 2019276359 A1 20201029; BR 112020021370 A2 20210119; CA 3097694 A1 20191205; CN 112313216 A 20210202; EP 3774776 A1 20210217; IL 278960 A 20210131; IL 278960 B1 20240401; JP 2021525270 A 20210924; JP 2023168629 A 20231124; JP 7390313 B2 20231201; KR 20210020882 A 20210224; MX 2020011636 A 20201207; PH 12020551806 A1 20210517; SG 11202009971Q A 20201127; US 2021163448 A1 20210603

DOCDB simple family (application)

EP 2019064214 W 20190531; AU 2019276359 A 20190531; BR 112020021370 A 20190531; CA 3097694 A 20190531; CN 201980036560 A 20190531; EP 19728645 A 20190531; IL 27896020 A 20201124; JP 2020565928 A 20190531; JP 2023174642 A 20231006; KR 20207034321 A 20190531; MX 2020011636 A 20190531; PH 12020551806 A 20201029; SG 11202009971Q A 20190531; US 201917047961 A 20190531